The results of the trial demonstrated that AIC316 showed safety and efficacy in patients with genital herpes.
In the trial, AIC316 was safe and well tolerated at all doses administered and and also reduces viral shedding in a dose dependent manner.
AiCuris CMO Marie-Paule Richard said the trial design that used shedding was important to show clearly the benefit of our drug and identify doses for further development.
"The significant clinical benefit of reduced lesions and recurrences combined with a good safety profile are encouraging for the further development of our drug," Richard said.